Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
The current price of MKGAF is $167.95 USD — it has increased by +1.88% in the past 24 hours. Watch Merck KGAA stock price performance more closely on the chart.
What is Merck KGAA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Merck KGAA stocks are traded under the ticker MKGAF.
Is Merck KGAA stock price growing?▼
MKGAF stock has risen by +0.58% compared to the previous week, the month change is a +4.28% rise, over the last year Merck KGAA has showed a +18.58% increase.
When is the next Merck KGAA earnings date?▼
Merck KGAA is going to release the next earnings report on March 4, 2027.
What were Merck KGAA earnings last quarter?▼
MKGAF earnings for the last quarter are 2.63 USD per share, whereas the estimation was 2.47 USD resulting in a +6.47% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Merck KGAA revenue for the last year?▼
Merck KGAA revenue for the last year amounts to 24.31B USD.
What is Merck KGAA net income for the last year?▼
MKGAF net income for the last year is 3B USD.
Does Merck KGAA pay dividends?▼
Yes, MKGAF dividends are paid annual. The last dividend per share was 2.57 . As of today, Dividend Yield (FWD)% is 1.56%.
How many employees does Merck KGAA have?▼
As of November 13, 2026, the company has 62,136 employees.
In which sector is Merck KGAA located?▼
Merck KGAA operates in the Health & Wellness sector.
When did Merck KGAA complete a stock split?▼
The last stock split for Merck KGAA was on June 30, 2014 with a ratio of 2:1.
Where is Merck KGAA headquartered?▼
Merck KGAA is headquartered in Darmstadt, Germany.